BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26292611)

  • 1. Redefining clinical risk classification in children with precursor B cell acute lymphoblastic leukemia using pre-treatment absolute lymphocyte count.
    Fungpipat P; Sophonphan J; Sosothikul D; Suppipat K
    Leuk Lymphoma; 2016; 57(4):953-6. PubMed ID: 26292611
    [No Abstract]   [Full Text] [Related]  

  • 2. The ratio of absolute lymphocyte count at interim of therapy to absolute lymphocyte count at diagnosis predicts survival in childhood B-lineage acute lymphoblastic leukemia.
    Cheng Y; Luo Z; Yang S; Jia M; Zhao H; Xu W; Tang Y
    Leuk Res; 2015 Feb; 39(2):144-50. PubMed ID: 25542697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The correlation between Pax5 deletion and patients survival in Iranian children with precursor B-cell acute lymphocytic leukemia.
    Moafi A; Zojaji A; Salehi R; Najafi Dorcheh S; Rahgozar S
    Cell Mol Biol (Noisy-le-grand); 2017 Aug; 63(8):19-22. PubMed ID: 28886309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absolute lymphocyte count is associated with minimal residual disease level in childhood B-cell precursor acute lymphoblastic leukemia.
    Shen HQ; Feng JH; Tang YM; Song H; Yang SL; Shi SW; Xu WQ
    Leuk Res; 2013 Jun; 37(6):671-4. PubMed ID: 23453285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Gore L; Locatelli F; Zugmaier G; Handgretinger R; O'Brien MM; Bader P; Bhojwani D; Schlegel PG; Tuglus CA; von Stackelberg A
    Blood Cancer J; 2018 Aug; 8(9):80. PubMed ID: 30190453
    [No Abstract]   [Full Text] [Related]  

  • 6. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
    Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
    Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of clinical features and prognostic significance of childhood T-lineage acute lymphoblastic leukemia].
    Zhang YL; Zhao WL; Nie SS; Guo DD; Ji ZH; Chai YH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Dec; 19(6):1496-500. PubMed ID: 22169311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts?
    Sędek Ł; Bulsa J; Sonsala A; Twardoch M; Wieczorek M; Malinowska I; Derwich K; Niedźwiecki M; Sobol-Milejska G; Kowalczyk JR; Mazur B; Szczepański T
    Cytometry B Clin Cytom; 2014 Sep; 86(5):329-39. PubMed ID: 24845957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detailed immunophenotyping of B-cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection.
    Theunissen PMJ; Sedek L; De Haas V; Szczepanski T; Van Der Sluijs A; Mejstrikova E; Nováková M; Kalina T; Lecrevisse Q; Orfao A; Lankester AC; van Dongen JJM; Van Der Velden VHJ;
    Br J Haematol; 2017 Jul; 178(2):257-266. PubMed ID: 28419441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical significance of SH2B3 (LNK) expression in paediatric B-cell precursor acute lymphoblastic leukaemia.
    Yano M; Imamura T; Asai D; Deguchi T; Hashii Y; Endo M; Sato A; Kawasaki H; Kosaka Y; Kato K; Hori H; Yumura-Yagi K; Hara J; Oda M; Horibe K
    Br J Haematol; 2018 Oct; 183(2):327-330. PubMed ID: 29082511
    [No Abstract]   [Full Text] [Related]  

  • 11. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
    DiGiuseppe JA; Fuller SG; Borowitz MJ
    Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD200/BTLA deletions in pediatric precursor B-cell acute lymphoblastic leukemia treated according to the EORTC-CLG 58951 protocol.
    Ghazavi F; Clappier E; Lammens T; Suciu S; Caye A; Zegrari S; Bakkus M; Grardel N; Benoit Y; Bertrand Y; Minckes O; Costa V; Ferster A; Mazingue F; Plat G; Plouvier E; Poirée M; Uyttebroeck A; van der Werff-Ten Bosch J; Yakouben K; Helsmoortel H; Meul M; Van Roy N; Philippé J; Speleman F; Cavé H; Van Vlierberghe P; De Moerloose B
    Haematologica; 2015 Oct; 100(10):1311-9. PubMed ID: 26137961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD10 AND CD34 expression in childhood acute lymphoblastic leukemia in Morocco: clinical relevance and outcome.
    Dakka N; Bellaoui H; Bouzid N; Khattab M; Bakri Y; Benjouad A
    Pediatr Hematol Oncol; 2009 Jun; 26(4):216-31. PubMed ID: 19437324
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment and outcome of IG-MYC
    Herbrueggen H; Mueller S; Rohde J; Arias Padilla L; Moericke A; Attarbaschi A; Zimmermann M; Ratei R; Brueggemann M; Siebert R; Goehring G; Schlegelberger B; Bradtke J; Klapper W; Woessmann W; Burkhardt B
    Leukemia; 2020 Mar; 34(3):942-946. PubMed ID: 31611629
    [No Abstract]   [Full Text] [Related]  

  • 15. A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children.
    Sutton R; Venn NC; Law T; Boer JM; Trahair TN; Ng A; Den Boer ML; Dissanayake A; Giles JE; Dalzell P; Mayoh C; Barbaric D; Revesz T; Alvaro F; Pieters R; Haber M; Norris MD; Schrappe M; Dalla Pozza L; Marshall GM
    Br J Haematol; 2018 Feb; 180(4):550-562. PubMed ID: 29194562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of mutations in FLT3, PTPN11 and RAS genes on the overall survival of pediatric B cell precursor acute lymphoblastic leukemia in Brazil.
    Barbosa TC; Andrade FG; Lopes BA; de Andrade CF; Mansur MB; Emerenciano M; Pombo-de-Oliveira MS
    Leuk Lymphoma; 2014 Jul; 55(7):1501-9. PubMed ID: 24067137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of outcome by early response in childhood acute lymphoblastic leukemia.
    Möricke A; Lauten M; Beier R; Odenwald E; Stanulla M; Zimmermann M; Attarbaschi A; Niggli F; Schrappe M
    Klin Padiatr; 2013 May; 225 Suppl 1():S50-6. PubMed ID: 23700057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Use of monoclonal antibodies in acute lymphoblastic leukemia in children. I. Immunological subclassification of acute lymphoblastic leukemia].
    Kołecki P; Radwańska U
    Pediatr Pol; 1988 Nov; 63(11):693-7. PubMed ID: 3253655
    [No Abstract]   [Full Text] [Related]  

  • 19. C-myc protein expression in B-cell acute lymphoblastic leukemia, prognostic significance?
    Allen A; Gill K; Hoehn D; Sulis M; Bhagat G; Alobeid B
    Leuk Res; 2014 Sep; 38(9):1061-6. PubMed ID: 25060305
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Acute lymphatic leukemia with pre-B-cell characteristics].
    Sauerbrey A; Häfer R; Zintl F
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(2):219-26. PubMed ID: 2475400
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.